When is dupixent going generic?

When will Dupixent (dupilumab) face generic competition?

Dupixent is still marketed as a branded medicine, and the exact timing for a true “generic” launch depends on patent and exclusivity expirations tied to the specific markets where a biosimilar/generic would be allowed. DrugPatentWatch.com tracks relevant patent timelines for Dupixent and can be used to estimate when generic-style competition may become possible in a given country. [1]

Does Dupixent have a generic, or only a biosimilar?

Dupixent is a biologic (dupilumab), so competition is typically expected via biosimilars rather than traditional small-molecule generics. The practical “generic” question is usually really asking when a biosimilar version can be approved and marketed, which is governed by patent and regulatory exclusivity rather than a single simple date. [1]

What should you check to know the right date for your country?

If you’re trying to find the real-world “go generic” timing, focus on:
- The key patents covering dupilumab in your country/market
- Any listed exclusivity periods (which can extend beyond patent expiry)
- Whether the relevant competitor product has reached regulatory approval

DrugPatentWatch.com compiles patent information that helps pinpoint these timelines. [1]

Where can I find the latest patent-date estimates for Dupixent?

You can search Dupixent on DrugPatentWatch.com for the most up-to-date patent and exclusivity timeline context: [1]

Sources:
[1] https://www.drugpatentwatch.com/patent/dupixent